Oligonucleotides are giving rise to a new generation of therapeutics—and Nitto Avecia is helping lead the way. With more than 25 years’ experience in oligonucleotide development and production, we are the partner of choice for pharmaceutical innovators creating new drugs with the power to transform treatment for a wide range of diseases.

In partnership with Nitto Avecia Pharma Services, Nitto Avecia is the first CMO that offers a comprehensive, end-to-end oligonucleotide solution. This offers the advantage of a single, expert partner handling the entire process—from drug substance through drug product manufacturing—with flexible solutions and consistent reliability and quality.

Biotechnology

Life Sciences

Pharmaceutical

Therapeutics

Nitto Avecia

Marie Laliberte

Kristy Bazaire

Derek Julian

Regina Hill

Brian Murphy Mba

Robert Coulter

Andrew Donaldson

Bethany Wood

Jennifer O'Brien

Kenji Nawa

Keri Dufault

Luke Altenau Cpm

Marc Gomez Caminals

Mark Boyle Mba, Cssbb

Steve Trahan

Theresa Vaughan

Natalia Olive

Michael Amend

Cindy Farnsworth

Michelle Leboeuf

Peter Tenaglia

Bob Gallinaro

Taylor Kleineick

Erica B. Blake

The Quality Control team at Nitto Avecia ensures the integrity and excellence of oligonucleotide therapeutics by meticulously testing and validating each step of drug production. This includes analyzing raw materials, intermediates, and final products to adhere to stringent regulatory standards, conducting thorough data reviews, and implementing robust quality assurance measures to guarantee the highest levels of compliance and reliability across the manufacturing process.

Quality Control

Research and Development Team

Project Management

Quality Control

About

Team members

Other teams at Nitto Avecia

Research and Development Team

Project Management